{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T17:16:59Z","timestamp":1692724619577},"reference-count":69,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.cld.2006.08.013","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T15:10:36Z","timestamp":1168441836000},"page":"867-880","source":"Crossref","is-referenced-by-count":5,"title":["New Therapies: Oral Inhibitors and Immune Modulators"],"prefix":"10.1016","volume":"10","author":[{"given":"Gary L.","family":"Davis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2006.08.013_bib1","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.282.5390.938","article-title":"Binding of hepatitis C virus to CD81","volume":"282","author":"Pileri","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.cld.2006.08.013_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0065-3527(04)63002-8","article-title":"Novel insights into hepatitis C virus replication and persistence","volume":"63","author":"Bartenschlager","year":"2004","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.cld.2006.08.013_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alfa therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.cld.2006.08.013_bib4","series-title":"Progress in liver diseases, vol. 8","first-page":"453","article-title":"The interferon system in acute and chronic viral hepatitis","author":"Peters","year":"1986"},{"key":"10.1016\/j.cld.2006.08.013_bib5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nature04078","article-title":"Evasion of intracellular host defense by hepatitis C virus","volume":"436","author":"Gale","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.cld.2006.08.013_bib6","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/clinids\/12.6.1139","article-title":"Molecular action of ribavirin","volume":"12","author":"Patterson","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.cld.2006.08.013_bib7","series-title":"Clinical applications of ribavirin","first-page":"33","article-title":"Overview of ribavirin treatment of infection caused by RNA viruses","author":"Crumpacker","year":"1984"},{"key":"10.1016\/j.cld.2006.08.013_bib8","doi-asserted-by":"crossref","first-page":"10462","DOI":"10.1021\/bi0344681","article-title":"Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase","volume":"42","author":"Vo","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.cld.2006.08.013_bib9","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: a randomized trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2006.08.013_bib10","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2006.08.013_bib11","doi-asserted-by":"crossref","first-page":"8400","DOI":"10.1128\/JVI.79.13.8400-8409.2005","article-title":"Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins","volume":"79","author":"Goffard","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.cld.2006.08.013_bib12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.4049\/jimmunol.173.1.446","article-title":"Incomplete humoral immunity against hepatitis C virus is linked with distinct recognition of putative multiple receptors by E2 envelope glycoprotein","volume":"173","author":"Heo","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cld.2006.08.013_bib13","doi-asserted-by":"crossref","first-page":"14199","DOI":"10.1073\/pnas.2335981100","article-title":"In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes","volume":"100","author":"Bartosch","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cld.2006.08.013_bib14","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1086\/432478","article-title":"Humoral immune response in acute hepatitis C virus infection","volume":"41","author":"Netski","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cld.2006.08.013_bib15","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1128\/JVI.80.6.2654-2664.2006","article-title":"Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients","volume":"80","author":"Eren","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.cld.2006.08.013_bib16","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hep.21088","article-title":"Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33","volume":"43","author":"Tarr","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2006.08.013_bib17","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/hep.20906","article-title":"Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity","volume":"42","author":"Schofield","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2006.08.013_bib18","doi-asserted-by":"crossref","first-page":"11095","DOI":"10.1128\/JVI.79.17.11095-11104.2005","article-title":"Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein","volume":"79","author":"Owsianka","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.cld.2006.08.013_bib19","doi-asserted-by":"crossref","first-page":"9224","DOI":"10.1128\/JVI.78.17.9224-9232.2004","article-title":"Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions","volume":"78","author":"Keck","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.cld.2006.08.013_bib20","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-128-10-199805150-00003","article-title":"Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation","volume":"128","author":"Feray","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2006.08.013_bib21","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/lt.20405","article-title":"A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients","volume":"11","author":"Davis","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2006.08.013_bib22","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.1073\/pnas.0402458101","article-title":"Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma","volume":"101","author":"Yu","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cld.2006.08.013_bib23","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/infdis\/173.4.822","article-title":"Effect of immune globulin on the prevention of experimental hepatitis C virus infection","volume":"173","author":"Krawczynski","year":"1996","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2006.08.013_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0168-8278(02)80095-2","article-title":"Anti-HCV human immunoglobulins for the prevention of graft infection in HCV-related liver transplantation: a pilot study","volume":"36","author":"Willems","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2006.08.013_bib25","first-page":"701A","article-title":"A phase I\/II study of monoclonal antibody HCV-ABXTL-68 in patients requiring liver transplant for HCV disease","volume":"42","author":"Schiano","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2006.08.013_bib26","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1128\/JVI.74.10.4824-4830.2000","article-title":"Structure-function analysis of hepatitis C virus envelope-CD81 binding","volume":"74","author":"Petracca","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.cld.2006.08.013_bib27","first-page":"750A","article-title":"A phase I safety and immunogenicity trial of a novel E1E2\/MF59C.1 hepatitis C vaccine candidate in healthy HCV-negative adults","volume":"42","author":"Di Bisceglie","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2006.08.013_bib28","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.vaccine.2004.02.002","article-title":"A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers","volume":"13","author":"Leroux-Roels","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.cld.2006.08.013_bib29","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1128\/JVI.74.13.5896-5901.2000","article-title":"Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence","volume":"74","author":"Seiler","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.cld.2006.08.013_bib30","doi-asserted-by":"crossref","first-page":"8217","DOI":"10.1128\/JVI.79.13.8217-8229.2005","article-title":"An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies","volume":"79","author":"Bartosch","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cld.2006.08.013_bib31","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0140-6736(05)75393-9","article-title":"Enteroviruses succumb to new drug","volume":"345","author":"McConnell","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2006.08.013_bib32","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1128\/JVI.71.2.1662-1666.1997","article-title":"The sequence element of the internal ribosome entry site and a 25-kilodalton cellular protein contribute to efficient internal initiation of translation of hepatitis C virus RNA","volume":"71","author":"Fukushi","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.cld.2006.08.013_bib33","series-title":"The desk encyclopedia of microbiology","first-page":"68","author":"Branch","year":"2004"},{"key":"10.1016\/j.cld.2006.08.013_bib34","first-page":"788A","article-title":"Preliminary analysis of a phase II study of HEPTAZYME, a nuclease resistant ribozyme targeting HCV RNA","volume":"36","author":"Tong","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2006.08.013_bib35","first-page":"362A","article-title":"A phase II, 12-week study of ISIS 14803, an antisense inhibitor of HCV for the treatment of chronic hepatitis C","volume":"36","author":"Gordon","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2006.08.013_bib36","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMra045004","article-title":"Therapeutic potential of RNA interference","volume":"351","author":"Stevenson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2006.08.013_bib37","doi-asserted-by":"crossref","first-page":"29604","DOI":"10.1074\/jbc.M505019200","article-title":"Hepatitis C virus NS2\/3 processing is required for NS3 stability and viral RNA replication","volume":"280","author":"Welbourn","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cld.2006.08.013_bib38","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1128\/JVI.67.5.2832-2843.1993","article-title":"Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites","volume":"67","author":"Grakoui","year":"1993","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cld.2006.08.013_bib39","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature02099","article-title":"An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus","volume":"426","author":"Lamarre","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.cld.2006.08.013_bib40","first-page":"234A","article-title":"Final results of a phase 1b, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor","volume":"42","author":"Reesink","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2006.08.013_bib41","doi-asserted-by":"crossref","first-page":"276A","DOI":"10.1016\/j.jhep.2004.11.012","article-title":"Combination therapy with the HCV protease inhibitor, SCH 503034, plus PEG-Intron in hepatitis C genotype-1 PEG-Intron non-responders: phase Ib results","volume":"42","author":"Zeuzem","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2006.08.013_bib42","doi-asserted-by":"crossref","unstructured":"Reesink HW, Zeuzem S, Weegink CJ, et\u00a0al. Initial results of a 14-day study of the hepatitis C virus inhibitor VX-950, in combination with peginterferon-alfa 2a [abstract 737]. J Hepatol 2006;44(Suppl 2):S272.","DOI":"10.1016\/S0168-8278(06)80737-3"},{"key":"10.1016\/j.cld.2006.08.013_bib43","doi-asserted-by":"crossref","unstructured":"Zeuzem S, Sarrazin C, Wagoner F, et\u00a0al. The HCV NS3 protease inhibitor SCH 503034 in combination with PEG-IFN-2b in the treatment of HCV-1 PEG IFN-2b nonresponders: antiviral activity and HCV variant analysis [abstract 78]. J Hepatol 2006;44(Suppl 2):S35.","DOI":"10.1016\/S0168-8278(06)80079-6"},{"key":"10.1016\/j.cld.2006.08.013_bib44","first-page":"233A","article-title":"Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (peg-IFN-\u03b1)","volume":"42","author":"Zeuzem","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2006.08.013_bib45","doi-asserted-by":"crossref","unstructured":"Kieffer T, Sarrazin C, Bartels D, et\u00a0al. Wild-type HCV NS3 protease re-emerges during follow-up after 14 days of dosing with VX-950 in patients with genotype 1 HCV [abstract 12]. J\u00a0Hepatol 2006;44(Suppl 2):S7.","DOI":"10.1016\/S0168-8278(06)80013-9"},{"key":"10.1016\/j.cld.2006.08.013_bib46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molcel.2005.05.014","article-title":"Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase","volume":"19","author":"Watashi","year":"2005","journal-title":"Mol Cell"},{"key":"10.1016\/j.cld.2006.08.013_bib47","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1128\/JVI.76.12.5974-5984.2002","article-title":"Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex","volume":"76","author":"Egger","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.cld.2006.08.013_bib48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/j.1460-2075.1996.tb00329.x","article-title":"Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus","volume":"15","author":"Behrens","year":"1996","journal-title":"EMBO J"},{"key":"10.1016\/j.cld.2006.08.013_bib49","first-page":"232A","article-title":"Randomized trial of Valopicitabine (NM283) alone or with PEG-Interferon vs. retreatment with PEG-Interferon plus ribavirin (PEGIFN\/RBV) in hepatitis C patients with previous non-response to PEGIFN.RBV: first interim results","volume":"42","author":"O'Brien","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2006.08.013_bib50","doi-asserted-by":"crossref","unstructured":"Dieterich D, Lawitz E, Nguyen T, et\u00a0al. Early clearance of HCV RNA with valopicitabine (NM283) plus peg-interferon in treatment-na\u00efve patients with HCV-1 infection: first results from a phase IIb trial [abstract 736]. J Hepatol 2006;44(Suppl 2):S271\u2013272.","DOI":"10.1016\/S0168-8278(06)80736-1"},{"key":"10.1016\/j.cld.2006.08.013_bib51","doi-asserted-by":"crossref","unstructured":"Roberts S, Cooksley G, Shaw D, et\u00a0al. Interim results of a multiple ascending dose study of R1626, a novel nucleoside analog targeting HCV polymerase in chronic HCV patients [abstract 731]. J Hepatol 2006;44(Suppl 2):S269.","DOI":"10.1016\/S0168-8278(06)80731-2"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2006.08.013_bib52","first-page":"A748","article-title":"Antiviral activity of the non-nucleoside polymerase inhibitor HCV-796 in patients with chronic hepatitis C virus: preliminary results from a randomized, double-blind, placebo-controlled, ascending multiple dose study","volume":"130","author":"Chandra","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2006.08.013_bib53","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1128\/JVI.80.9.4510-4520.2006","article-title":"Diverse effects of cyclosporine on hepatitis C virus strain replication","volume":"80","author":"Ishii","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.cld.2006.08.013_bib54","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.bbrc.2006.03.059","article-title":"Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811","volume":"343","author":"Goto","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cld.2006.08.013_bib55","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/lt.20576","article-title":"The challenge of progressive hepatitis C following liver transplantation","volume":"12","author":"Davis","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2006.08.013_bib56","doi-asserted-by":"crossref","first-page":"11878","DOI":"10.1073\/pnas.96.21.11878","article-title":"Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents","volume":"96","author":"Zitzmann","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cld.2006.08.013_bib57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0014-5793(98)00525-0","article-title":"Alpha-glucosidase inhibitors as potential broad based anti-viral agents","volume":"430","author":"Mehta","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1016\/j.cld.2006.08.013_bib58","doi-asserted-by":"crossref","first-page":"8400","DOI":"10.1128\/JVI.79.13.8400-8409.2005","article-title":"Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins","volume":"79","author":"Goffard","year":"2005","journal-title":"J Virol"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2006.08.013_bib59","first-page":"A784","article-title":"Results of a phase IIa dose ranging study of orally administered Celgosivir as monotherapy in chronic hepatitis C genotype-1 patients","volume":"130","author":"Yoshida","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2006.08.013_bib60","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ni1087","article-title":"The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses","volume":"5","author":"Yoneyama","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cld.2006.08.013_bib61","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1112","article-title":"Toll-like receptor control of the adaptive immune responses","volume":"5","author":"Iwasaki","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cld.2006.08.013_bib62","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/1079990041689665","article-title":"Induction and regulation of IFNs during viral infections","volume":"24","author":"Malmgaard","year":"2004","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.cld.2006.08.013_bib63","doi-asserted-by":"crossref","first-page":"16739","DOI":"10.1074\/jbc.M414139200","article-title":"Distinct poly-I: C and virus-activated signaling pathways leading to interferon-\u03b2 production in hepatocytes","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cld.2006.08.013_bib64","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signaling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cld.2006.08.013_bib65","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1128\/AAC.33.9.1487","article-title":"Broad-spectrum in vivo antiviral activity of 7-thia-8-oxoguanosine, a novel immunopotentiating agent","volume":"33","author":"Smee","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2006.08.013_bib66","first-page":"A282","article-title":"Isatoribine, a toll-like receptor 7 agonist, significantly reduced plasma viral load in a clinical proof-of-concept study in patients with chronic hepatitis C virus infection","volume":"40","author":"Horsman","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2006.08.013_bib67","doi-asserted-by":"crossref","unstructured":"McHutchison JG, Bacon BR, Gordon SC, et\u00a0al. Final results of a multicenter phase 1b randomized, placebo-controlled, dose escalation trial of CPG 10101 in patients with chronic hepatitis C virus [abstract 111]. J Hepatol 2006;44(Suppl 2):S49.","DOI":"10.1016\/S0168-8278(06)80112-1"},{"key":"10.1016\/j.cld.2006.08.013_bib68","doi-asserted-by":"crossref","unstructured":"McHutchison JG, Ghalib R, Lawitz E, et\u00a0al. Early response to CPG 10101 in combination with pegylated interferon and\/or ribavirin in chronic HCV genotype 1 infected patients with prior relapse response [abstract 730]. J Hepatol 2006;44(Suppl 2):S269.","DOI":"10.1016\/S0168-8278(06)80730-0"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2006.08.013_bib69","first-page":"A668","article-title":"Oral IDN-6556, an anti-apoptotic caspase inhibitor, lowers aminotransferases in HCV patients","volume":"126","author":"Schiff","year":"2004","journal-title":"Gastroenterology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326106000298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326106000298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T17:59:57Z","timestamp":1587319197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326106000298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S1089326106000298"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2006.08.013","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}